Qb Flu

Drug Profile

Qb Flu

Alternative Names: gH1-Qbeta; H1N1 influenza VLP vaccine - A*STAR/Cytos; Influenza A H1N1 virus-like particle vaccine - A*STAR/Cytos; Influenza-A virus vaccine - Cytos; Qb-Flu; Qb-VLP vaccine; Recombinant flu vaccine - A*STAR/Cytos

Latest Information Update: 27 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Agency for Science, Technology and Research
  • Developer Agency for Science, Technology and Research; Cytos Biotechnology; Singapore Immunology Network
  • Class Influenza virus vaccines; Virus-like particle vaccines
  • Mechanism of Action B cell stimulants; Helper-inducer T-lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Influenza A virus H1N1 subtype

Most Recent Events

  • 13 May 2014 Qb Flu is available for licensing as of 05 May 2014. http://www.cytos.com
  • 05 May 2014 Suspended - Phase-I for Influenza-A virus H1N1 subtype in Singapore (Parenteral)
  • 29 Jan 2014 Immunogenicity data from a phase I trial in Influenza-A virus H1N1 subtype (prevention, in volunteers) released by Cytos Biotechnology and Agency for Science, Technology and Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top